Ramsden S C, Mann K, McConnell C, Hastings R
National Genetics Reference Laboratory (Manchester), Department of Medical Genetics, Saint Mary's Hospital, Hathersage Road, Manchester M13 OJH, UK.
Prenat Diagn. 2007 May;27(5):404-8. doi: 10.1002/pd.1698.
Prenatal diagnosis using rapid molecular genetic techniques is now a widely used method for detecting the most prevalent chromosomal aneuploidies. The object of this work was to develop a methodology for delivering external quality assessment (EQA) appropriate to the needs of routine diagnostic testing laboratories.
We have provided three rounds of EQA using 15 different samples over 3 years. The scheme has developed to assess both the genotyping accuracy of the results and the appropriateness of the clinical reports issued to the referring clinician.
Participation in the EQA scheme has increased from 9 to 27 laboratories from across Europe over the three sample distributions. All laboratories have used quantitative fluorescence-PCR (QF-PCR) to analyse these samples except for a sole participant in 2006 who used multiplex ligation-dependent probe amplification (MLPA). In total 265 samples have been distributed, of which four (1.5%) were not reported due to technical failures and one (0.4%) was reported incorrectly and must be regarded as a genotyping error.
We have demonstrated a significant and increasing demand for EQA in the rapid detection of aneuploidies in UK and other European laboratories. Using the methodologies described, we have had a very low rate of technical failures and demonstrated a high level of genotyping accuracy. However, the quality of the clinical reports was variable and suggestions are made for improvement.
使用快速分子遗传学技术进行产前诊断现已成为检测最常见染色体非整倍体的广泛应用方法。本研究的目的是开发一种适合常规诊断检测实验室需求的外部质量评估(EQA)方法。
我们在3年时间里使用15种不同样本提供了三轮EQA。该方案已发展到既能评估结果的基因分型准确性,又能评估发给转诊临床医生的临床报告的恰当性。
在三轮样本分发中,参与EQA方案的实验室从欧洲各地的9家增加到了27家。除了2006年唯一一名使用多重连接依赖探针扩增(MLPA)的参与者外,所有实验室都使用定量荧光PCR(QF-PCR)分析这些样本。总共分发了265个样本,其中4个(1.5%)因技术故障未报告,1个(0.4%)报告错误,必须视为基因分型错误。
我们已经证明英国和其他欧洲实验室对非整倍体快速检测中的EQA有显著且不断增加的需求。使用所描述的方法,我们的技术故障率非常低,并且证明了高水平的基因分型准确性。然而,临床报告的质量参差不齐,并提出了改进建议。